IL-12p35诱导的CD19+IL-10+调节性B细胞通过JAK2/STAT3/HIF-1α通路调控免疫性血小板减少症患者的功能性T细胞亚群
研究从免疫性血小板减少症(ITP)患者及健康人外周血单个核细胞中分离CD19+ B细胞与CD4+ T细胞,发现ITP患者IL-10+CD19+ B细胞比例及IL12A mRNA水平低于健康人。抗IL-12p35抗体处理可减少CD19+ B细胞中IL-10+群体并调控CD4+CD25- T细胞分化,重组IL-12p35则呈相反效应,且该效应可被HIF-1α和JAK2/STAT3抑制剂逆转。结论为IL-12p35诱导的CD19+IL-10+ B细胞经JAK2/STAT3/HIF-1α通路调控ITP患者CD4+ T细胞亚群。
要点
- ITP患者外周血IL-10+CD19+ B细胞比例及IL12A mRNA水平低于健康人。
- 抗IL-12p35抗体减少CD19+ B细胞中IL-10+群体并调控CD4+CD25- T细胞分化。
- 重组IL-12p35诱导的IL-10+ B细胞增加及HIF-1α表达可被HIF-1α和JAK2/STAT3抑制剂逆转。
核心结论
- IL-12p35诱导的CD19+IL-10+ B细胞通过JAK2/STAT3/HIF-1α信号通路调控ITP患者的CD4+ T细胞亚群。
研究设计与样本
- 研究从ITP患者及健康人外周血单个核细胞中分离CD19+ B细胞与CD4+ T细胞。
- 将CD4+CD25- T细胞与经抗IL-12p35抗体或IL-12p35重组蛋白处理的CD19+ B细胞共培养。
- 采用酶联免疫吸附试验、蛋白质印迹、实时定量PCR和流式细胞术评估IL-12p35对CD19+ B细胞的影响。
主要发现
- ITP患者外周血单个核细胞中IL-10+CD19+ B细胞比例及IL12A mRNA水平低于健康人。
- 抗IL-12p35抗体处理的CD19+ B细胞减少CD19+ B细胞中IL-10+群体并调控CD4+CD25- T细胞分化。
- 重组IL-12p35呈现与抗IL-12p35抗体相反的效应。
- 重组IL-12p35诱导的CD19+ B细胞中IL-10+群体增加及HIF-1α表达可被HIF-1α和JAK2/STAT3抑制剂逆转。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary immune thrombocytopenia (ITP) is a condition characterized by immune-mediated platelet loss due to excessive destruction and/or insufficient production. IL-12p35 is involved in autoimmune uveitis; however, its role in ITP remains unknown. In the study, CD19+ B and CD4+ T cells were isolated from peripheral blood mononuclear cells (PBMCs) of patients with ITP and healthy individuals. CD4+CD25- T cells were cocultured with the CD19+ B cells treated with anti-IL-12p35 antibody or IL-12p35 recombinant protein. The impact of IL-12p35 on CD19+ B cells was assessed by enzyme-linked immunosorbent assay, Western blotting, quantitative real-time PCR and flow cytometry. PBMCs from patients with ITP showed lower proportions of IL-10+CD19+ B cells and decreased mRNA levels of IL-12p35-coding gene IL12A than those from healthy individuals. Anti-IL-12p35 antibody-treated CD19+ B cells could reduce the population of IL-10+ in CD19+ B cells and regulate the differentiation of CD4+CD25- T cells, while recombinant IL-12p35 demonstrated the opposite effects. Moreover, the increased IL-10+ B-cell population and HIF-1α expression in CD19+ B cells induced by recombinant IL-12p35 were reversed by HIF-1α and JAK2/STAT3 inhibitors. In conclusion, CD19+IL-10+ B cells induced by IL-12p35 regulate CD4+ T-cell subsets in patients with ITP via the JAK2/STAT3/HIF-1α signalling pathway.
引用
- Hua F, Sun L, Li Y, et al. CD19+IL-10+ regulatory B cells induced by IL-12p35 regulates functional T-cell subsets in patients with immune thrombocytopenia. Br J Haematol. 2025. PMID: 40415408. doi:10.1111/bjh.20173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。